An attorney representing a man injured by the antipsychotic medication Risperdal painted the drugmaker Johnson & Johnson as a malicious company that pushed for the drug’s off-label use in children despite evidence linking the drug to excessive growth of breast tissue in boys and young men all in an effort to maximize profits over the safety of children.

“They have a target. They know who they want to make money from: kids. And not just any kids. Kids who are the most vulnerable in our society. Kids with autism and Asperger’s and ADD,” Houston lawyer Jason Itkin of Arnold & Itkin told the Philadelphia jury Tuesday morning.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]